Results 71 to 80 of about 38,575 (293)

From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications [PDF]

open access: yes, 2016
Statins are recommended as first-line therapy for patients with hypercholesterolaemia. A sizable proportion of patients, however, does not reach therapeutic goals, is statin intolerant, or, despite optimal statin therapy, is at high risk of ischaemic ...
Alessandro, Sionis   +7 more
core   +1 more source

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9

open access: yesEuropean Heart Journal, 2019
Aims Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases.
H. Jang   +20 more
semanticscholar   +1 more source

In vitro characterization of the novel proprotein convertase PC7. [PDF]

open access: yesJournal of Biological Chemistry, 1997
Biochemical and enzymatic characterization of the novel proprotein convertase rat PC7 (rPC7) was carried out using vaccinia virus recombinants overexpressed in mammalian BSC40 cells. Pro-PC7 is synthesized as a glycosylated zymogen (101 kDa) and processed into mature rPC7 (89 kDa) in the endoplasmic reticulum.
J S, Munzer   +10 more
openaire   +3 more sources

Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

open access: yesTürk Biyokimya Dergisi
We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA).
Deniz Levent   +4 more
doaj   +1 more source

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives

open access: yesMedical Review, 2021
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases.
Zhou Jun   +4 more
doaj   +1 more source

Proprotein Convertase Processing Enhances Peroxidasin Activity to Reinforce Collagen IV [PDF]

open access: yes, 2016
The basement membrane (BM) is a form of extracellular matrix that underlies cell layers in nearly all animal tissues. Type IV collagen, a major constituent of BMs, is critical for tissue development and architecture.
Bhave, Gautam, Colon, Selene
core   +2 more sources

Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality

open access: yesJournal of Internal Medicine, 2018
Diabetes mellitus is linked to premature mortality of virtually all causes. Furin is a proprotein convertase broadly involved in the maintenance of cellular homeostasis; however, little is known about its role in the development of diabetes mellitus and ...
C. Fernandez   +7 more
semanticscholar   +1 more source

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li   +3 more
doaj   +1 more source

Role of Proprotein Convertases in Prostate Cancer Progression

open access: yesNeoplasia, 2012
Better understanding of the distinct and redundant functions of the proprotein convertase (PC) enzyme family within pathophysiological states has a great importance for potential therapeutic strategies. In this study, we investigated the functional redundancy of PCs in prostate cancer in the commonly used androgen-sensitive LNCaP and the androgen ...
François Boudreau   +4 more
openaire   +4 more sources

Proprotein Convertase Subtilisin Kexin 9 Inhibitors [PDF]

open access: yesCardiology Clinics, 2018
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy ...
A. Pirillo, A. L. Catapano
openaire   +3 more sources

Home - About - Disclaimer - Privacy